Skip to main content

IgA Nephropathy clinical trials at UCSF

3 research studies open to eligible people

Showing trials for
  • Zigakibart in Adults With IgA Nephropathy

    open to eligible people ages 18 years and up

    Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

    San Francisco, California and other locations

  • Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.

    San Francisco, California and other locations

  • Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18 years and up

    The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

    San Francisco, California and other locations

Last updated: